<h1>Domestic firms launch affordable pertuzumab biosimilar for HER2 breast cancer; assess regulatory, IP, labeling, pricing, and liability risks</h1> A domestic healthcare company, in partnership with a biosciences firm, launched an affordable biosimilar of pertuzumab for HER2-positive breast cancer, citing alignment with the government's access-to-care objectives. Legally relevant issues include regulatory compliance for biosimilar approval, labeling and efficacy claims, intellectual property and patent risk, pricing and competition implications, and potential product liability and indemnity exposure. Commercial collaboration terms, manufacturing quality controls and pharmacovigilance obligations will affect risk allocation and regulatory standing. Any promotional statements must comply with advertising and healthcare regulations to avoid enforcement or civil claims.